

Genetic Predisposition and Risk Assessment for Ovarian Cancer: Implications for Screening and Prevention

Josiane Aurah*

Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya

Abstract

Genetic predisposition plays a pivotal role in the development of ovarian cancer, with mutations in genes such as

Advances in genomic research have transformed our understanding of ovarian cancer susceptibility, paving the way

Introduction

Genetic predisposition plays a pivotal role in the development of ovarian cancer, with mutations in genes such as BRCA1 and BRCA2 being the most well-known. Advances in genomic research have transformed our understanding of ovarian cancer susceptibility, paving the way for personalized screening and prevention strategies.

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer.

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 BRCA2: 65% 40% 0%

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

BRCA1 and BRCA2 mutations are associated with an increased risk of ovarian cancer. The risk is higher for BRCA1 carriers (approximately 65%) compared to BRCA2 carriers (approximately 40%).

*Corresponding author: Josiane Aurah, Department of Obstetrics and

Received:

Editor Assigned:

Reviewed:

Revised:

Published:

Citation:

Copyright: © Josiane A terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and

].

D.

].